Antimicrobial Agents Practice Questions

Q: Which of the following monoclonal antibodies can be used in Clostridium difficile infection?

Bezlotoxumab. **Explanation:** **Correct Answer: D. Bezlotoxumab** **Mechanism and Rationale:** *Clostridium difficile* infection (CDI) causes pathology primarily through the release of two exotoxins: **Toxin A (Enterotoxin)** and **Toxin B (Cytotoxin)**. While antibiotics like Vancomycin or Fidaxomicin target the bacteria itself, **Bezlotoxumab** is a human monoclonal antibody that binds specifically to **Toxin B**. By neutralizing the toxin, it prevents damage to the intestinal mucosa and significantly reduces the risk of **recurrent CDI** in high-risk patients. It is administered as a single intravenous infusion. **Analysis of Incorrect Options:** * **A. Canakinumab:** An **Interleukin-1β (IL-1β) inhibitor** used in systemic juvenile idiopathic arthritis and periodic fever syndromes. * **B. Dupilumab:** An **IL-4 and IL-13 receptor antagonist** used in the management of moderate-to-severe atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. * **C. Certolizumab:** A **TNF-alpha inhibitor** (specifically a PEGylated Fab' fragment) used in Crohn’s disease and rheumatoid arthritis. **High-Yield Clinical Pearls for NEET-PG:** * **Bezlotoxumab vs. Actoxumab:** While Bezlotoxumab targets Toxin B, Actoxumab (targets Toxin A) was also studied but did not show clinical efficacy on its own. * **Drug of Choice for CDI:** Oral **Fidaxomicin** or oral **Vancomycin** are first-line agents. Metronidazole is now reserved for non-severe cases where other options are unavailable. * **Key Side Effect:** Use Bezlotoxumab with caution in patients with **congestive heart failure (CHF)**, as it may exacerbate the condition.

Q: A 37-year-old immunosuppressed patient with renal failure develops sepsis. Which of the following antibiotics, if used, would require a major reduction in dosage?

Tobramycin. **Explanation:** The core concept tested here is the **route of elimination** of antimicrobial agents. In patients with renal failure, drugs primarily excreted unchanged by the kidneys require significant dose adjustments to prevent toxicity. **Why Tobramycin is correct:** Tobramycin is an **Aminoglycoside**. Aminoglycosides are highly polar, water-soluble molecules that are excreted almost entirely (90%+) via **glomerular filtration** in an unchanged form. In renal failure, their clearance decreases proportionally with the Creatinine Clearance (CrCl). Failure to reduce the dose or increase the dosing interval leads to accumulation, significantly increasing the risk of **nephrotoxicity** and **ototoxicity**. **Why the other options are incorrect:** * **Erythromycin:** This macrolide is primarily metabolized by the liver and excreted in the **bile**. No major dose adjustment is needed in renal failure. * **Doxycycline:** Unlike other tetracyclines, doxycycline is excreted mainly via the **feces** (enterohepatic circulation). It is the "tetracycline of choice" in renal failure. * **Isoniazid:** This antitubercular drug undergoes **hepatic acetylation**. While metabolites are excreted renally, a major dose reduction is generally not required unless there is concurrent hepatic impairment. **High-Yield NEET-PG Pearls:** * **"Safe" in Renal Failure:** Ceftriaxone, Doxycycline, Erythromycin, Clindamycin, and Linezolid (no major adjustment). * **Contraindicated in Renal Failure:** Tetracycline (except Doxycycline), Nitrofurantoin, and Nalidixic acid. * **Aminoglycoside Monitoring:** Therapeutic Drug Monitoring (TDM) is essential. They exhibit **concentration-dependent killing** and a significant **post-antibiotic effect (PAE)**.

Q: Thioacetazone has cross-resistance with which of the following drugs?

Ethionamide. **Explanation:** The correct answer is **Ethionamide**. **Why Ethionamide is correct:** Thioacetazone and Ethionamide are both members of the **thioamide** group of antitubercular drugs. They share a similar chemical structure and a common mechanism of action: both act as prodrugs that are activated by the monooxygenase enzyme **EthA**. Once activated, they inhibit the enzyme **InhA** (enoyl-ACP reductase), which is essential for mycolic acid synthesis in the mycobacterial cell wall. Because they utilize the same activation pathway (EthA), a mutation in the *ethA* gene leads to resistance in both drugs, resulting in **cross-resistance** [5]. **Why other options are incorrect:** * **Isoniazid (INH):** While INH also inhibits the InhA enzyme, it is activated by a different enzyme, **KatG** (catalase-peroxidase). Therefore, resistance to INH (usually via KatG mutation) does not automatically confer resistance to Thioacetazone [5]. * **Rifampicin:** This drug acts by inhibiting DNA-dependent RNA polymerase (rpoB gene). Its mechanism is entirely distinct from mycolic acid synthesis inhibitors [4]. * **Ethambutol:** This drug inhibits arabinosyl transferase, interfering with the synthesis of arabinogalactan in the cell wall. It does not share a metabolic pathway or target with Thioacetazone. **High-Yield Clinical Pearls for NEET-PG:** * **Thioacetazone & HIV:** Thioacetazone is strictly contraindicated in HIV-positive patients due to the high risk of life-threatening **Stevens-Johnson Syndrome (SJS)** and Toxic Epidermal Necrolysis (TEN). * **Ethionamide Side Effects:** It is notorious for causing intense GI irritation and a metallic taste [5]. * **Cross-resistance Summary:** Always remember the

Q: Which of the following agents is NOT recommended for the treatment of chronic Hepatitis B?

Famciclovir. **Explanation:** The treatment of chronic Hepatitis B Virus (HBV) focuses on suppressing viral replication to prevent cirrhosis and hepatocellular carcinoma. **Why Famciclovir is the correct answer:** **Famciclovir** is a prodrug of penciclovir, primarily used for Herpes Simplex (HSV) and Varicella-Zoster (VZV) infections. While it possesses some inhibitory activity against the HBV DNA polymerase, clinical trials demonstrated that it is significantly **less effective** than other available agents and carries a high risk of developing resistance. Consequently, it is **not recommended** or FDA-approved for the treatment of chronic Hepatitis B. **Analysis of Incorrect Options:** * **Interferon (Alpha-2b or Pegylated):** These are immunomodulators that enhance the host immune response against HBV. They are first-line options, especially for patients desiring a finite duration of therapy. * **Lamivudine:** A nucleoside reverse transcriptase inhibitor (NRTI). Although it was the first oral anti-HBV drug, its use has declined due to high rates of resistance (YMDD mutation); however, it remains a recognized treatment. * **Adefovir:** A nucleotide analog that inhibits HBV DNA polymerase. While less potent than newer agents like Tenofovir or Entecavir, it is a recognized treatment for chronic HBV. **High-Yield Clinical Pearls for NEET-PG:** * **Drugs of Choice:** Currently, **Tenofovir** (TDF/TAF) and **Entecavir** are the preferred first-line oral agents due to high potency and a high genetic barrier to resistance. * **Mechanism:** Most oral HBV drugs are NRTIs that inhibit the viral **DNA polymerase** (which has reverse transcriptase activity). * **Pregnancy:** Tenofovir is the preferred agent for treating HBV in pregnant women to prevent vertical transmission. * **Side Effect:** Interferon is notorious for causing "flu-like symptoms" and depression.

Q: Which antibody is used in the treatment of RSV infection?

Palivizumab. **Explanation:** **Palivizumab** is the correct answer. It is a humanized monoclonal antibody directed against the **F (fusion) protein** of the Respiratory Syncytial Virus (RSV). By binding to this protein, the antibody prevents the virus from fusing with and entering the host respiratory epithelial cells. It is primarily used for **immunoprophylaxis** in high-risk infants (e.g., those with prematurity, bronchopulmonary dysplasia, or congenital heart disease) to prevent severe lower respiratory tract infections. **Analysis of Incorrect Options:** * **Omalizumab (Option A):** An anti-IgE antibody used in the management of moderate-to-severe persistent allergic asthma and chronic urticaria. It prevents IgE from binding to mast cells and basophils. * **Rituximab (Option C):** A chimeric monoclonal antibody against the **CD20** antigen found on B-cells. It is used in Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), and autoimmune conditions like Rheumatoid Arthritis. * **Daclizumab (Option D):** An IL-2 receptor (CD25) antagonist. It was historically used to prevent renal transplant rejection and in multiple sclerosis (though largely withdrawn due to hepatic toxicity). **High-Yield Clinical Pearls for NEET-PG:** * **Route:** Palivizumab is administered via **intramuscular** injection once a month during the RSV season. * **Target:** Remember the **"F"** in Palivizumab for **F**usion protein. * **Ribavirin:** While Palivizumab is for *prevention*, aerosolized Ribavirin is the antiviral agent used for the *treatment* of severe RSV bronchiolitis in hospitalized children. * **Nirsevimab:** A newer, long-acting monoclonal antibody recently approved for RSV prevention in all infants, which may appear in future exams.

Q: Which of the following statements about Penicillin G is true?

It is used for the treatment of rat bite fever.. **Explanation:** **Correct Answer: C. It is used for the treatment of rat bite fever.** Penicillin G (Benzylpenicillin) remains the drug of choice for **Rat-bite fever**, caused by *Streptobacillus moniliformis* or *Spirillum minus*. Despite the emergence of resistance in other bacteria, Penicillin G is highly effective against these specific pathogens, as well as *Treponema pallidum* (Syphilis) and *Neisseria meningitidis*. **Analysis of Incorrect Options:** * **A. Broad spectrum:** Penicillin G is a **narrow-spectrum** antibiotic. It is primarily active against Gram-positive cocci (Streptococci), Gram-positive bacilli (Anthrax, Diphtheria), and certain Gram-negative cocci and spirochetes. It lacks significant activity against most Gram-negative rods. * **B. Administered orally:** Penicillin G is **acid-labile** and is destroyed by gastric acid. Therefore, it must be administered parenterally (IV or IM). Penicillin V (Phenoxymethylpenicillin) is the acid-stable oral alternative. * **D. Probenecid interaction:** Probenecid **increases** the duration of action of Penicillin G. It competes for the organic anion transporter (OAT) in the renal tubules, inhibiting the tubular secretion of penicillin, thereby raising its plasma concentration and half-life. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Penicillin G is the DOC for Syphilis, Gas gangrene (*C. perfringens*), Tetanus, and Actinomycosis. * **Jarisch-Herxheimer Reaction:** A classic adverse effect seen when treating Syphilis with Penicillin G due to the release of endotoxins from dying spirochetes. * **Repository Forms:** Procaine and Benzathine Penicillin are long-acting IM formulations used to maintain sustained therapeutic levels.

Q: Which of the following drugs is NOT hepatotoxic?

Linezolid. **Explanation:** The correct answer is **Linezolid**. Hepatotoxicity is a common adverse effect of many antimicrobial agents, but Linezolid is primarily known for its hematological and neurological toxicities rather than hepatic damage. **1. Why Linezolid is the correct answer:** Linezolid, an Oxazolidinone, is not typically associated with significant hepatotoxicity. Its primary dose-limiting side effect is **bone marrow suppression** (especially thrombocytopenia) when used for more than 2 weeks. It is also associated with peripheral/optic neuropathy and **Serotonin Syndrome** when co-administered with SSRIs due to its weak MAO-inhibitory activity. **2. Why the other options are wrong:** * **Erythromycin estolate:** This specific salt of Erythromycin is notorious for causing **cholestatic jaundice**. It is considered a hypersensitivity reaction and is more common in adults than children. * **Rifampicin:** A key component of ATT (Anti-Tubercular Therapy), it is a known hepatotoxin. It causes an asymptomatic rise in transaminases and can lead to clinical hepatitis. It is also a potent **enzyme inducer**. * **Tetracycline:** High doses (especially IV) can cause **acute fatty liver infiltration**, particularly in pregnant women, which can be fatal. **Clinical Pearls for NEET-PG:** * **Drug-Induced Liver Injury (DILI):** Paracetamol (Acetaminophen) is the most common cause of dose-dependent hepatotoxicity (treated with N-acetylcysteine). * **ATT Hepatotoxicity:** The order of hepatotoxicity is **Isoniazid > Pyrazinamide > Rifampicin**. Ethambutol is non-hepatotoxic. * **Halothane:** A classic anesthetic agent associated with "Halothane Hepatitis." * **Valproate:** Can cause idiosyncratic hepatotoxicity, especially in children under 2 years.

Q: The dose of which of the following antibiotics does not require alteration in renal failure?

Erythromycin. **Explanation:** The primary factor determining whether an antibiotic dose requires adjustment in renal failure is its **route of elimination**. Drugs primarily excreted via the kidneys require dose reduction to prevent toxicity, whereas drugs metabolized by the liver or excreted via bile do not. **Correct Option: C. Erythromycin** Erythromycin is a macrolide antibiotic primarily metabolized by the liver and excreted in the **bile**. Since its clearance is independent of renal function, no dose adjustment is necessary in patients with renal impairment. **Incorrect Options:** * **A. Vancomycin:** This glycopeptide is almost entirely excreted unchanged by glomerular filtration. It is highly nephrotoxic; thus, dosing must be strictly adjusted based on creatinine clearance or serum drug monitoring. * **B. Ethambutol:** Approximately 80% of this antitubercular drug is excreted unchanged in the urine. Accumulation in renal failure can lead to **optic neuritis**. * **C. Metronidazole:** While primarily metabolized by the liver, its metabolites are renally excreted. In end-stage renal disease (ESRD), a dose reduction (usually 50%) is often recommended to prevent the accumulation of active metabolites. **High-Yield Clinical Pearls for NEET-PG:** * **"Safe" Antibiotics in Renal Failure (No/Minimal adjustment):** Erythromycin, Azithromycin, Ceftriaxone, Doxycycline, Chloramphenicol, Clindamycin, and Rifampicin. * **Doxycycline** is the tetracycline of choice in renal failure because it is excreted via feces (enterohepatic circulation). * **Ceftriaxone** is a third-generation cephalosporin that does not require adjustment due to dual excretion (biliary and renal).

Q: All of the following parasitic infestations are indications for the use of Mebendazole, except?

Strongyloides. **Explanation:** **Mebendazole** is a broad-spectrum anthelmintic belonging to the Benzimidazole group. It works by inhibiting **microtubule synthesis** (binding to β-tubulin) in the parasite, leading to glucose depletion and death. **Why Strongyloides is the Correct Answer:** While Mebendazole has some activity against many nematodes, it is **not** the drug of choice for *Strongyloides stercoralis*. Strongyloidiasis requires drugs that can penetrate deeper into the intestinal mucosa and systemic circulation. The gold standard treatment for *Strongyloides* is **Ivermectin** (first-line) or **Albendazole** (second-line). Mebendazole has poor systemic absorption, making it less effective for this specific parasite. **Analysis of Incorrect Options:** * **A. Roundworm (*Ascaris lumbricoides*):** Mebendazole is highly effective and a standard treatment for ascariasis. * **B. Whipworm (*Trichuris trichiura*):** Mebendazole is considered the drug of choice for whipworm infections, often requiring a 3-day course. * **C. Hookworm (*Ancylostoma duodenale/Necator americanus*):** Mebendazole is a primary treatment option for hookworm infestations. **High-Yield Clinical Pearls for NEET-PG:** 1. **Mechanism of Action:** Inhibition of microtubule polymerization by binding to β-tubulin. 2. **Drug of Choice (DOC) Summary:** * **Ivermectin:** DOC for *Strongyloides* and Onchocerciasis (River blindness). * **Albendazole:** DOC for Hydatid disease (*Echinococcus*) and Neurocysticercosis (*Taenia solium*). * **Diethylcarbamazine (DEC):** DOC for Filariasis. 3. **Contraindication:** Benzimidazoles are generally avoided in the **first trimester of pregnancy** due to potential embryotoxicity.

Question 1

Which of the following monoclonal antibodies can be used in Clostridium difficile infection?

Accepted Answer

Bezlotoxumab

Answer

Canakinumab

Answer

Dupilumab

Answer

Certolizumab

Question 2

A 37-year-old immunosuppressed patient with renal failure develops sepsis. Which of the following antibiotics, if used, would require a major reduction in dosage?

Accepted Answer

Tobramycin

Answer

Erythromycin

Answer

Doxycycline

Answer

Isoniazid

Question 3

Which of the following drugs CANNOT be used to treat infections caused by Bacteroides fragilis?

Accepted Answer

Amikacin

Answer

Metronidazole

Answer

Trovafloxacin

Answer

Vancomycin

Question 4

Thioacetazone has cross-resistance with which of the following drugs?

Accepted Answer

Ethionamide

Answer

Isoniazid (INH)

Answer

Rifampicin

Answer

Ethambutol

Question 5

Which of the following agents is NOT recommended for the treatment of chronic Hepatitis B?

Accepted Answer

Famciclovir

Answer

Interferon

Answer

Lamivudine

Answer

Adefovir

Question 6

Which antibody is used in the treatment of RSV infection?

Accepted Answer

Palivizumab

Answer

Omalizumab

Answer

Rituximab

Answer

Daclizumab

Question 7

Which of the following statements about Penicillin G is true?

Accepted Answer

It is used for the treatment of rat bite fever.

Answer

It has a broad spectrum of activity.

Answer

It can be administered orally.

Answer

Probenecid, when given with Penicillin G, decreases its duration of action.

Question 8

Which of the following drugs is NOT hepatotoxic?

Accepted Answer

Linezolid

Answer

Erythromycin estolate

Answer

Rifampicin

Answer

Tetracycline

Question 9

The dose of which of the following antibiotics does not require alteration in renal failure?

Accepted Answer

Erythromycin

Answer

Vancomycin

Answer

Ethambutol

Answer

Metronidazole

Question 10

All of the following parasitic infestations are indications for the use of Mebendazole, except?

Accepted Answer

Strongyloides

Answer

Roundworm

Answer

Whipworm

Answer

Hookworm

Antimicrobial Agents — MCQs

Antimicrobial Agents — MCQs

On this page

Practice by Chapter

Want unlimited practice?